To make high-quality research more accessible and easier to explore.
Fields:
3 results
✕ Clear filters
Corporate Governance Reform and Executive Incentives: Implications for Investments and Risk Taking
We investigate the mechanism through which the Sarbanes Oxley Act ( SOX ) was associated with changes in corporate investment strategies. We document that the passage of the governance regulations in SOX was followed by a significant decline in pay‐performance sensitivity (Delta) and incentives to take risk (Vega) in CEO s' compensation contracts. These changes in compensation contracts are related to a decline in investments, including research and development expenditures, capital investments and acquisitions. Moreover, consistent with the rules in SOX directly affecting CEO s' incentives to take risk, we document that the decline in investments exceeds the amount that would be expected from changes in compensation packages alone. Finally, we also find evidence that the changes in investments are related to lower operating performances of firms, suggesting that these changes were costly to investors. Our evidence speaks to the debate on how corporate governance regulation interacts with firms' and managers' incentives, and ultimately affects corporate operating and investment strategies. Our study suggests that one indirect cost of such regulations in SOX is the significant reductions in corporate risk‐taking activities in the post‐ SOX period. The changes in investments were in part due to changes in executive compensation contracts and in part related to increased executives' personal costs of engaging in risky activities.
Measuring Real Activity Management
To test hypotheses about earnings management, many studies investigate managers' manipulation of real activities (real earnings management, REM). Tests using measures of abnormal REM hinge critically on the measurement of normal real activities. Yet, there is no systematic evidence on the statistical properties of commonly used REM measures. We provide such evidence by documenting the Type I error rates and power of the test of the REM measures commonly used in the literature. We find these measures are often misspecified with Type I error rates that deviate from the nominal significance level of the test, especially in samples of firms with extreme performance or firm characteristics. We also compare the specification and power of traditional REM measures with performance‐matched REM measures to see if the latter provide better specified and more powerful tests. While performance‐matched REM measures are not immune from misspecification in all settings, in general they are better specified under the null hypothesis (i.e., in terms of Type I errors) than are traditional REM measures. Comparisons of the power to detect abnormal REM reveal that neither approach, traditional or performance‐matched, is consistently more powerful than the other in terms of detecting abnormal REM ranging from 1 to 10 percent of (lagged) total assets. The absence of a dominant approach to measure abnormal REM leads us to recommend that future researchers report results using both traditional and performance‐matched measures, so that readers are able to clearly assess the reliability of the inferences drawn about the magnitude and significance of the abnormal REM documented in a given study.